{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:25:31Z","timestamp":1791318331397,"version":"4.3.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"58","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The first evidence that cannabinoids may have in vitro and in vivo antineoplastic activity against tumor cell lines and animal tumor models was published in the Journal of the National Cancer Institute nearly 50\u2009years ago. Cannabinoids appear to induce apoptosis in rodent brain tumors by way of direct interaction with the cannabinoid receptor. They may inhibit angiogenesis and tumor cell invasiveness. Despite preclinical findings, attempts to translate the benefits from bench to bedside have been limited. This session provides a review of the basic science supporting the use of cannabinoids in gliomas, paired with the first randomized clinical trial of a cannabis-based therapy for glioblastoma multiforme. Another preclinical presentation reports the effects of cannabinoids on triple-negative breast cancer cell lines and how cannabidiol may affect tumors. The session\u2019s second human trial raises concerns about the use of botanical cannabis in patients with advanced cancer receiving immunotherapy suggesting inferior outcomes.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgab010","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T11:14:24Z","timestamp":1631272464000},"page":"107-113","source":"Crossref","is-referenced-by-count":12,"title":["Cancer Treatment: Preclinical &amp; Clinical"],"prefix":"10.1093","volume":"2021","author":[{"given":"Donald I","family":"Abrams","sequence":"first","affiliation":[{"name":"Hematology-Oncology Division, Department of Medicine, University of California, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Velasco","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Biology, Complutense University, Madrid, Spain"},{"name":"Group of Cannabinoid Signaling in Cancer Cells, Division of Oncology Research, Instituto de Investigaci\u00f3n Sanitaria San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Twelves","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K","family":"Ganju","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Division, Cancer Center, Emek Medical Center, Afula,Israel"},{"name":"Bruce Rappaport Faculty of Medicine, Technion\/Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"issue":"3","key":"2021120111525451300_lgab010-B1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/55.3.597","article-title":"Antineoplastic activity of cannabinoids","volume":"55","author":"Munson","year":"1975","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2021120111525451300_lgab010-B2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrc3247","article-title":"Towards the use of cannabinoids as antitumour agents","volume":"12","author":"Velasco","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2021120111525451300_lgab010-B3","volume-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","year":"2017"},{"issue":"8","key":"2021120111525451300_lgab010-B4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41416-021-01259-3","article-title":"A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma","volume":"124","author":"Twelves","year":"2021","journal-title":"Br J Cancer"},{"issue":"9","key":"2021120111525451300_lgab010-B5","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.3390\/cancers12092447","article-title":"Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome","volume":"12","author":"Bar-Sela","year":"2020","journal-title":"Cancers"},{"key":"2021120111525451300_lgab010-B6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2015.05.010","article-title":"The use of cannabinoids as anticancer agents","volume":"64","author":"Velasco","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"2021120111525451300_lgab010-B7","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3390\/cancers12113203","article-title":"Cannabidiol (CBD) as a promising anti-cancer drug","volume":"12","author":"Seltzer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2021120111525451300_lgab010-B8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bjc.6603236","article-title":"A pilot clinical study of delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme","volume":"95","author":"Guzman","year":"2006","journal-title":"Br J Cancer"},{"issue":"4","key":"2021120111525451300_lgab010-B9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2006.03.005","article-title":"The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumour cells","volume":"9","author":"Carracedo","year":"2006","journal-title":"Cancer Cell"},{"issue":"7","key":"2021120111525451300_lgab010-B10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4161\/auto.5.7.9508","article-title":"TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action","volume":"5","author":"Salazar","year":"2009","journal-title":"Autophagy"},{"issue":"11","key":"2021120111525451300_lgab010-B11","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/15548627.2016.1213927","article-title":"Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization","volume":"12","author":"Hernandez-Tiedra","year":"2016","journal-title":"Autophagy"},{"issue":"6","key":"2021120111525451300_lgab010-B12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/cdd.2010.170","article-title":"Stimulation of the midkine\/ALK axis renders glioma cells resistant to cannabinoid antitumoral action","volume":"18","author":"Lorente","year":"2011","journal-title":"Cell Death Differ"},{"issue":"13","key":"2021120111525451300_lgab010-B13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/glia.20856","article-title":"Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis","volume":"57","author":"Lorente","year":"2009","journal-title":"Glia"},{"issue":"11","key":"2021120111525451300_lgab010-B14","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.7150\/thno.41450","article-title":"Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells","volume":"10","author":"Lopez-Valero","year":"2020","journal-title":"Theranostics"},{"key":"2021120111525451300_lgab010-B15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bcp.2018.09.007","article-title":"Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide","volume":"157","author":"Lopez-Valero","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"2021120111525451300_lgab010-B16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bcp.2018.08.023","article-title":"Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma","volume":"157","author":"Lopez-Valero","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2021120111525451300_lgab010-B17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1535-7163.MCT-10-0688","article-title":"A combined preclinical therapy of cannabinoids and temozolomide against glioma","volume":"10","author":"Torres","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2021120111525451300_lgab010-B18","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-14-0402","article-title":"The combination of cannabidiol and delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model","volume":"13","author":"Scott","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"suppl 5","key":"2021120111525451300_lgab010-B19","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol"},{"issue":"10","key":"2021120111525451300_lgab010-B20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2021120111525451300_lgab010-B21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.critrevonc.2016.01.018","article-title":"Therapeutic options in recurrent glioblastoma\u2014an update","volume":"99","author":"Seystahl","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"2021120111525451300_lgab010-B22","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2006.08.1661","article-title":"Prognostic factors for survival in adult patients with recurrent glioma enrolled on new approaches to brain tumour therapy \u201cNABTT\u201d CNS consortium phase I and II clinical trials","volume":"25","author":"Carson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021120111525451300_lgab010-B23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2021120111525451300_lgab010-B24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/nos273","article-title":"Standards of care for treatment of recurrent glioblastoma\u2014are we there yet?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol"},{"key":"2021120111525451300_lgab010-B25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-94-007-4719-7_11","article-title":"Cannabinoid signaling in glioma cells","volume":"986","author":"Ellert-Miklaszewska","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2021120111525451300_lgab010-B26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-013-1277-1","article-title":"Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas","volume":"116","author":"Rocha","year":"2014","journal-title":"J Neurooncol"},{"issue":"8","key":"2021120111525451300_lgab010-B27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41416-021-01265-5","article-title":"Cannabinoids in glioblastoma multiforme\u2014hype or hope?","volume":"124","author":"Doherty","year":"2021","journal-title":"Br J Cancer"},{"issue":"15","key":"2021120111525451300_lgab010-B28","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.18632\/oncotarget.2233","article-title":"Cannabinoids as therapeutic agents in cancer: current status and future implications","volume":"5","author":"Chakravarti","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"2021120111525451300_lgab010-B29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1158\/1940-6207.CAPR-10-0181","article-title":"Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis","volume":"4","author":"Preet","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"11","key":"2021120111525451300_lgab010-B30","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1158\/1535-7163.MCT-09-0448","article-title":"Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer","volume":"8","author":"Qamri","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2021120111525451300_lgab010-B31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12032-013-0653-1","article-title":"Triple-negative breast cancer: new perspectives for novel therapies","volume":"30","author":"Mahamodhossen","year":"2013","journal-title":"Med Oncol"},{"issue":"4","key":"2021120111525451300_lgab010-B32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.molonc.2014.12.010","article-title":"Modulation of the tumor microenvironment and inhibition of EGF\/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancer","volume":"9","author":"Elbaz","year":"2015","journal-title":"Mol Oncol"},{"issue":"9","key":"2021120111525451300_lgab010-B33","doi-asserted-by":"crossref","first-page":"e23901","DOI":"10.1371\/journal.pone.0023901","article-title":"Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion","volume":"6","author":"Nasser","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"2021120111525451300_lgab010-B34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","article-title":"A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray","volume":"69","author":"Stott","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"21","key":"2021120111525451300_lgab010-B35","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2021120111525451300_lgab010-B36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"issue":"71","key":"2021120111525451300_lgab010-B37","doi-asserted-by":"crossref","first-page":"33459","DOI":"10.18632\/oncotarget.9663","article-title":"TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer","volume":"9","author":"Elbaz","year":"2018","journal-title":"Oncotarget"},{"key":"2021120111525451300_lgab010-B38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fimmu.2013.00034","article-title":"The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses","volume":"4","author":"Santoni","year":"2013","journal-title":"Front Immunol"},{"issue":"2","key":"2021120111525451300_lgab010-B39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/cancers11020129","article-title":"Prospects for the use of cannabinoids in oncology and palliative care practice: a review of the evidence","volume":"11","author":"Dzier\u017canowski","year":"2019","journal-title":"Cancers (Basel"},{"issue":"2","key":"2021120111525451300_lgab010-B40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-020-00811-2","article-title":"Medical cannabis in oncology: a valuable unappreciated remedy or an undesirable risk?","volume":"22","author":"Abu-Amna","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"2021120111525451300_lgab010-B41","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00520-019-04774-5","article-title":"Pharmacological evidence of medicinal cannabis in oncology: a systematic review","volume":"27","author":"Brown","year":"2019","journal-title":"Support Care Cancer"},{"issue":"7","key":"2021120111525451300_lgab010-B42","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4155\/fmc.09.93","article-title":"Cannabinoids as novel anti-inflammatory drugs","volume":"1","author":"Nagarkatti","year":"2009","journal-title":"Future Med Chem"},{"issue":"1","key":"2021120111525451300_lgab010-B43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/can.2018.0014","article-title":"The anti-inflammatory properties of terpenoids from cannabis","volume":"3","author":"Gallily","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"2021120111525451300_lgab010-B44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000508840","article-title":"Cannabis and inflammatory mediators","volume":"27","author":"Lima","year":"2021","journal-title":"Eur Addict Res"},{"issue":"7","key":"2021120111525451300_lgab010-B45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2021120111525451300_lgab010-B46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s13311-015-0374-6","article-title":"The endocannabinoid system and its modulation by phytocannabinoids","volume":"12","author":"Di Marzo","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"4","key":"2021120111525451300_lgab010-B47","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2021120111525451300_lgab010-B48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drudis.2016.08.005","article-title":"Targeting the endocannabinoid system: Future therapeutic strategies","volume":"22","author":"Aizpurua-Olaizola","year":"2017","journal-title":"Drug Discov Today"},{"issue":"2","key":"2021120111525451300_lgab010-B49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2009.03.019","article-title":"Endocannabinoids and immune regulation","volume":"60","author":"Pandey","year":"2009","journal-title":"Pharmacol Res"},{"issue":"4","key":"2021120111525451300_lgab010-B50","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol Rev"},{"issue":"4-5","key":"2021120111525451300_lgab010-B51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000481824","article-title":"Immunoregulatory role of cannabinoids during infectious disease","volume":"24","author":"Hern\u00e1ndez-Cervantes","year":"2017","journal-title":"Neuroimmunomodulation"},{"issue":"9","key":"2021120111525451300_lgab010-B52","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"17","key":"2021120111525451300_lgab010-B53","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021120111525451300_lgab010-B54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1634\/theoncologist.2018-0383","article-title":"Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies","volume":"24","author":"Taha","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"2021120111525451300_lgab010-B55","doi-asserted-by":"crossref","first-page":"14542","DOI":"10.1038\/s41598-017-15026-z","article-title":"Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation","volume":"7","author":"Zgair","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2021120111525451300_lgab010-B56","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bcp.2008.06.022","article-title":"The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT)","volume":"76","author":"Kaplan","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2021120111525451300_lgab010-B57","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11481-013-9485-1","article-title":"Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction","volume":"8","author":"Robinson","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"2021120111525451300_lgab010-B58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11481-015-9603-3","article-title":"Effects of cannabinoids on T-cell function and resistance to infection","volume":"10","author":"Eisenstein","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"issue":"15","key":"2021120111525451300_lgab010-B59","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.289.15.1929-a","article-title":"Modulation of the immune system in cannabis users","volume":"289","author":"Pacifici","year":"2003","journal-title":"JAMA"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2021\/58\/107\/41409100\/lgab010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2021\/58\/107\/41409100\/lgab010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T17:28:02Z","timestamp":1638379682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2021\/58\/107\/6446189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":59,"journal-issue":{"issue":"58","published-online":{"date-parts":[[2021,11,27]]},"published-print":{"date-parts":[[2021,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgab010","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,11,27]]}}}